Web Analysis for Zometa - zometa.com
Learn more Zometa® (zoledronic acid) & its approved indications, courtesy of Novartis Oncology.
zometa.com is 2 decades 5 years old. It is a domain having com extension. This website is estimated worth of $ 8.95 and have a daily income of around $ 0.15. As no active threats were reported recently by users, zometa.com is SAFE to browse.
PageSpeed Score
Siteadvisor Rating
Traffic Report
Daily Unique Visitors: | Not Applicable |
Daily Pageviews: | Not Applicable |
Estimated Valuation
Income Per Day: | $ 0.15 |
Estimated Worth: | $ 8.95 |
Search Engine Indexes
Google Indexed Pages: | Not Applicable |
Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
Google Backlinks: | Not Applicable |
Bing Backlinks: | Not Applicable |
Safety Information
Google Safe Browsing: | No Risk Issues |
Siteadvisor Rating: | No Risk Issues |
WOT Trustworthiness: | Not Applicable |
WOT Child Safety: | Not Applicable |
Website Ranks & Scores
Alexa Rank: | Not Applicable |
Domain Authority: | Not Applicable |
Web Server Information
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
H1 Headings: | 1 | H2 Headings: | 5 |
H3 Headings: | Not Applicable | H4 Headings: | Not Applicable |
H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
Total IFRAMEs: | 1 | Total Images: | 2 |
Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Websites Hosted on Same IP (i.e. 217.114.92.50)
AFINITOR® (everolimus) | Official Site from Novartis
The official website for AFINITOR® (everolimus) tablets. Find information about AFINITOR®, the conditions it treats, and Important Safety Information.
SANDOSTATIN® LAR Depot (octreotide acetate) for Acromegaly and Carcino
Learn about SANDOSTATIN® LAR Depot (octreotide acetate) for injectable suspension for acromegaly and carcinoid syndrome. See Important Safety Information.
Home | EXJADE® (deferasirox) FILM-COATED TABLETS
Learn about EXJADE®, an iron chelation therapy for the management of chronic iron overload due to blood transfusions. See safety & product information.
FEMARA® (letrozole) | 1L Treatment for HR+ Metastatic Breast Cancer
Discover FEMARA® (letrozole), an approved treatment from Novartis Oncology for HR+ breast cancer in postmenopausal women. Learn about FEMARA® side effects & see recommended FEMARA® dosage information.
HTTP Header Analysis
Date: Sun, 18 Jun 2017 10:02:16 GMT
Content-Type: text/html; charset=utf-8
Connection: close
X-Drupal-Cache: HIT
X-Content-Type-Options: nosniff
Content-Language: en
X-Frame-Options: SAMEORIGIN
X-UA-Compatible: IE=edge,chrome=1
Link: <https://www.novartisoncology.com/news/product-portfolio/zometa>; rel="canonical",<https://www.novartisoncology.com/node/11811>; rel="shortlink"
Cache-Control: public, max-age=21600
Last-Modified: Sun, 18 Jun 2017 10:00:55 GMT
Expires: Sun, 18 Jun 2017 16:02:16 GMT
Vary: Accept-Encoding
X-Request-ID: a4ad3c38-de85-4b4c-b8bb-5dfdba74823c
X-AH-Environment: prod
CF-Cache-Status: EXPIRED
Server: cloudflare-nginx
CF-RAY: 370d69784dbf5e70-TPA
Content-Encoding: gzip
Domain Information
Domain Nameserver Information
Host | IP Address | Country | |
---|---|---|---|
mia03.digex.com | 216.255.129.246 | United States of America | |
dns1.novartis.com | 160.62.4.7 | Switzerland | |
dns2.novartis.com | 160.62.7.59 | Switzerland |
DNS Record Analysis
Host | Type | TTL | Extra |
---|---|---|---|
zometa.com | A | 86393 |
IP: 217.114.92.50 |
zometa.com | NS | 86399 |
Target: dns1.novartis.com |
zometa.com | NS | 86399 |
Target: dns2.novartis.com |
zometa.com | NS | 86399 |
Target: mia03-1.digex.com |
zometa.com | SOA | 86399 |
MNAME: dns1.novartis.com RNAME: hostmaster.novartis.com Serial: 2016122006 Refresh: 28800 Retry: 7200 Expire: 604800 Minimum TTL: 3600 |
Full WHOIS Lookup
Registry Domain ID: 2454532_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2017-06-18T00:10:01-0700
Creation Date: 1998-11-18T00:00:00-0800
Registrar Registration Expiration Date: 2017-11-16T21:00:00-0800
Registrar: MarkMonitor, Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: abusecomplaints@markmonitor.com
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientUpdateProhibited (https://www.icann.org/epp#clientUpdateProhibited)
Domain Status: clientTransferProhibited (https://www.icann.org/epp#clientTransferProhibited)
Domain Status: clientDeleteProhibited (https://www.icann.org/epp#clientDeleteProhibited)
Registry Registrant ID:
Registrant Name: Domain Admin
Registrant Organization: Novartis AG
Registrant Street: P.O. Box CH-4002,
Registrant City: Basel
Registrant State/Province:
Registrant Postal Code: 4002
Registrant Country: CH
Registrant Phone: +1.2083895740
Registrant Phone Ext:
Registrant Fax: +1.2083895799
Registrant Fax Ext:
Registrant Email: novartis.domains@markmonitor.com
Registry Admin ID:
Admin Name: Domain Admin
Admin Organization: MarkMonitor, Inc.
Admin Street: 3540 East Longwing Lane, Suite 300
Admin City: Meridian
Admin State/Province: ID
Admin Postal Code: 83646
Admin Country: US
Admin Phone: +1.2083895740
Admin Phone Ext:
Admin Fax: +1.2083895799
Admin Fax Ext:
Admin Email: novartis.domains@markmonitor.com
Registry Tech ID:
Tech Name: Domain Admin
Tech Organization: MarkMonitor, Inc.
Tech Street: 3540 East Longwing Lane, Suite 300
Tech City: Meridian
Tech State/Province: ID
Tech Postal Code: 83646
Tech Country: US
Tech Phone: +1.2083895740
Tech Phone Ext:
Tech Fax: +1.2083895799
Tech Fax Ext:
Tech Email: novartis.domains@markmonitor.com
Name Server: mia03.digex.com
Name Server: dns2.novartis.com
Name Server: dns1.novartis.com
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2017-06-18T03:02:21-0700